Rheumatoid Arthritis and Cardiovascular Mortality
Rheumatoid arthritis (RA) has long been associated with elevated mortality and morbidity. Patients with RA have significantly higher rates than the overall population of ischemic heart disease, atherosclerosis, peripheral vascular disease, congestive... Read More

Safety Updates for Biologic Agents Used to Treat Rheumatoid Arthritis
Increasing clinical experience with biologic agents as treatments for rheumatoid arthritis (RA) is yielding increasing data regarding their safety. A number of tumor necrosis factor (TNF) blockers (ie, adalimumab, etanercept, and infliximab) are ap... Read More

Development of Tocilizumab for the Treatment of Rheumatoid Arthritis
Though the cause of rheumatoid arthritis (RA) has not been elucidated, current treatments target the inflammatory process. Available biologic agents act by inhibiting tumor necrosis factor (ie, etanercept, adalimumab, and infliximab), interleukin-1 (... Read More

American College of Rheumatology Issues New Guidelines for the Treatment of Rheumatoid Arthritis
In 2008, the American College of Rheumatology (ACR) issued new guidelines for the use of nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) in treating rheumatoid arthritis (RA).¹ These guidelines represent the first t... Read More